CAJ | 학술논문

非酒精性脂肪肝是以肝实质细胞发生脂肪堆积和脂肪变性为主要特征，并伴随机体脂质代谢紊乱的一种获得性代谢疾病。以高脂饲料喂养大鼠，建立非酒精性脂肪肝大鼠模型；以低、中、高剂量（10、50、100 mg·kg-1）表没食子儿茶素没食子酸酯（EGCG）分别灌胃模型大鼠，探讨茶叶中EGCG对非酒精性脂肪肝大鼠的调脂保肝作用。结果表明，与模型组相比，EGCG能显著降低血清中甘油三酯（TG）、总胆固醇（TC）和低密度脂蛋白-胆固醇（LDL-C）含量，降低丙氨酸氨基转移酶（ALT）和天冬氨酸转氨酶（AST）活性水平，提高高密度脂蛋白-胆固醇（HDL-C）的含量，改善大鼠肝脏氧化应激状态。此外，肝脏病理切片显示，EGCG能减少肝细胞中脂滴的形成，同时脂质代谢相关基因表达量分析显示，EGCG能调理肝脏的脂质代谢。综合以上实验结果表明，EGCG能显著改善非酒精性脂肪肝大鼠的脂质代谢紊乱和脂肪性肝损伤。
비주정성지방간시이간실질세포발생지방퇴적화지방변성위주요특정，병반수궤체지질대사문란적일충획득성대사질병。이고지사료위양대서，건립비주정성지방간대서모형；이저、중、고제량（10、50、100 mg·kg-1）표몰식자인다소몰식자산지（EGCG）분별관위모형대서，탐토다협중EGCG대비주정성지방간대서적조지보간작용。결과표명，여모형조상비，EGCG능현저강저혈청중감유삼지（TG）、총담고순（TC）화저밀도지단백-담고순（LDL-C）함량，강저병안산안기전이매（ALT）화천동안산전안매（AST）활성수평，제고고밀도지단백-담고순（HDL-C）적함량，개선대서간장양화응격상태。차외，간장병리절편현시，EGCG능감소간세포중지적적형성，동시지질대사상관기인표체량분석현시，EGCG능조리간장적지질대사。종합이상실험결과표명，EGCG능현저개선비주정성지방간대서적지질대사문란화지방성간손상。
Non-alcoholic fatty liver disease (NAFLD) is a pathological metabolic syndrome performed as the fat accumulation and/or fatty degeneration in the liver, which is directly re levant to lipid metabolic disorder. In order to investigate the effects of EGCG from tea on regulating lipid metabolism and alleviating liver injury in rats with NAFLD, NAFLD model rats were established by feeding a high fat diet, and then the rats of EGCG protective groups were given daily oral administration of EGCG with three doses of 10, 50 mg·kg-1 and 100 mg·kg-1, respectively. The results showed that, compared with the model group, EGCG could decrease serum levels of triglyceride (TG), total cholesterol (TC) and low density lipoprotein-cholesterol (LDL-C), increase serum level of high density lipoprotein-cholesterol (HDL-C), reduce activities of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in the serum, and ameliorate liver oxidative stress. Also, histological analysis showed that EGCG could reduce the formation of lipid droplets in the liver cells, and RT-PCR analysis showed that EGCG could regulate the expression of genes involved in lipid metabolism. Taken together, these experiment results indicated that EGCG from tea effectively alleviate lipid metabolic disorder and lipid-induced liver injury.